Wow are you ignorant of the science. First of all Lizzness is given at a small fraction of the dose required for the SGYP drug. Why is that? Because Lizzness is more stable due to its overall structure. It has 3 disulfide bonds which stabilize the molecule far better than the 2 disulfide bonds in the SGYP drug candidate. Next, the SGYP drug is a single change from the naturally occurring agonist for the target receptor, whereas the IRWD drug is much different. Finally, as indicated below, first to market wins. Period.
You know your science, I like that, but you sure as hell don't know the name of the drug on the market. Getting Linzess wrong once is understandable, but twice...I call it it Linzmess, but I'm trying to be funny. What's your angle?
SGYP is not born yet and it needs to eat, drink and change diapers for a few years while SCMP Amitiza with more indications is hugging the market. It is a proven drug and its pediatric and also elderly versions will be in the market in next few quarters before SGYP gets one indication if any.